COMMUNIQUÉ DE PRESSE

par SYNLAB

Region Stockholm engages SYNLAB to expand its medical diagnostic services in Sweden

EQS-News: SYNLAB / Key word(s): Miscellaneous
Region Stockholm engages SYNLAB to expand its medical diagnostic services in Sweden

31.03.2026 / 11:01 CET/CEST
The issuer is solely responsible for the content of this announcement.


 
  • The Health and Medical Care Committee awarded SYNLAB Sverige AB the contract for the provision of services within clinical laboratory medicine in the Stockholm region.
  • This agreement enables SYNLAB to strengthen the region’s diagnostic infrastructure and significantly expand its role and presence within the healthcare landscape in Sweden.
  • SYNLAB will work closely with the regional authority to expand its network while continuing to provide reliable, accessible and high-quality service that benefits patients and professionals.

 

SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, announced today that SYNLAB Sverige AB has been selected by Region Stockholm to provide medical diagnostic services throughout the county. The decision reflects the region’s confidence in SYNLAB as a capable and trusted partner for the future of healthcare.

The new agreement brings a modern and high-quality medical diagnostic solution to Region Stockholm. It allows SYNLAB to expand its presence in the region and strengthen an essential part of the healthcare system’s diagnostic infrastructure. The assignment covers clinical chemistry including pharmacology, clinical microbiology, clinical immunology, and clinical pathology and cytology, as well as the processes needed to ensure safe and efficient sample handling. Within the framework of the agreement, SYNLAB will also operate a network of blood collection points (BCPs) in the western parts of the Stockholm County, the inner city and the southwestern areas. The agreement spans a period of five years, with the option to extend, and operations are planned to begin in April 2027.

“We are proud of the trust placed in us to deliver laboratory and sample-collection services to Region Stockholm. Medical diagnostics are vital to the healthcare system. We look forward to working with the region to expand SYNLAB’s modern and reliable diagnostic service and to provide strong value for patients and healthcare professionals,” says Johanna Kristoffersson, Chief Executive Officer of SYNLAB Sverige AB.

With its strong track record of building and managing large-scale operations tailored to local needs and environment, SYNLAB looks forward to expanding its services on behalf of Region Stockholm and contributing to care excellence across the wider region.

– Ends –

For more information:

 

Media Contact
Daniel Herbert, FTI Consulting 
+ 49 (0) 151 12263834 
media-contact@synlab.com

 

 

About SYNLAB

  • SYNLAB Group is a leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporations.
  • Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
  • SYNLAB operates in more than 20 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 23,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.
  • SYNLAB performed around 600 million laboratory tests and achieved revenues of €2.54 billion in 2025.
  • More information can be found on www.synlab.com.


31.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2301322  31.03.2026 CET/CEST

Voir toutes les actualités de SYNLAB